29 Sep by Vitaliy Dadalyan ImmunoPrecise Reports Revenue of $3.8 Million and Adjusted EBITDA of $932,000 for the First Quarter of Fiscal 2021 VICTORIA, BC, Sept. 29, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD.
